Last reviewed · How we verify
0.75 MAC desflurane
0.75 MAC desflurane, marketed by Changi General Hospital, is an established anesthetic agent in the healthcare sector. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of revenue data and key trial results, which may limit strategic planning and market positioning.
At a glance
| Generic name | 0.75 MAC desflurane |
|---|---|
| Also known as | 0.75 MAC desflurane (Suprane) |
| Sponsor | Changi General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Use of 0.5 and 0.75 MAC Desflurane in Patients Undergoing Spinal Surgery (PHASE4)
- Comparison of Low Versus Normal Flow Anesthesia on Cerebral Oxygenation and Bispectral Index in Morbidly Obese Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.75 MAC desflurane CI brief — competitive landscape report
- 0.75 MAC desflurane updates RSS · CI watch RSS
- Changi General Hospital portfolio CI